Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
Total Valuation
ALX Oncology Holdings has a market cap or net worth of $282.96M. The enterprise value is $102.99M.
Market Cap$282.96M
Enterprise Value$102.99M
Share Statistics
ALX Oncology Holdings has 131,608,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding131,608,280
Owned by Insiders10.30%
Owned by Institutions13.26%
Financial Efficiency
ALX Oncology Holdings’s return on equity (ROE) is -3.91 and return on invested capital (ROIC) is -253.96%.
Return on Equity (ROE)-3.91
Return on Assets (ROA)-1.72
Return on Invested Capital (ROIC)-253.96%
Return on Capital Employed (ROCE)-2.92
Revenue Per Employee0.00
Profits Per Employee-1.56M
Employee Count65
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ALX Oncology Holdings is ―. ALX Oncology Holdings’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.33
Price to Fair Value2.33
Price to FCF-0.72
Price to Operating Cash Flow-1.39
PEG Ratio0.02
Income Statement
In the last 12 months, ALX Oncology Holdings had revenue of 0.00 and earned -101.69M in profits. Earnings per share was -1.90.
Revenue0.00
Gross Profit0.00
Operating Income-100.85M
Pretax Income-101.69M
Net Income-101.69M
EBITDA-100.85M
Earnings Per Share (EPS)-1.90
Cash Flow
In the last 12 months, operating cash flow was -84.14M and capital expenditures -212.00K, giving a free cash flow of -84.35M billion.
Operating Cash Flow-84.14M
Free Cash Flow-84.35M
Free Cash Flow per Share-0.64
Dividends & Yields
ALX Oncology Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.33
52-Week Price Change186.67%
50-Day Moving Average1.91
200-Day Moving Average1.30
Relative Strength Index (RSI)52.14
Average Volume (3m)670.12K
Important Dates
ALX Oncology Holdings upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateFeb 27, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
ALX Oncology Holdings as a current ratio of 2.07, with Debt / Equity ratio of 20.08%
Current Ratio2.07
Quick Ratio2.07
Debt to Market Cap0.09
Net Debt to EBITDA0.11
Interest Coverage Ratio-62.95
Taxes
In the past 12 months, ALX Oncology Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ALX Oncology Holdings EV to EBITDA ratio is -0.49, with an EV/FCF ratio of -0.59.
EV to Sales0.00
EV to EBITDA-0.49
EV to Free Cash Flow-0.59
EV to Operating Cash Flow-0.59
Balance Sheet
ALX Oncology Holdings has $44.79M in cash and marketable securities with $5.22M in debt, giving a net cash position of $39.57M billion.
Cash & Marketable Securities$44.79M
Total Debt$5.22M
Net Cash$39.57M
Net Cash Per Share$0.30
Tangible Book Value Per Share$0.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ALX Oncology Holdings is $4.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.75
Price Target Upside120.93% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast31.98%